Hematologic Oncology | Specialty

Treatment Options in Relapsed/Refractory Multiple Myeloma

August 10th 2020

Options for Transplant Ineligible Patients in Multiple Myeloma

August 10th 2020

Maintenance Therapy in Multiple Myeloma

August 10th 2020

The Role of Transplant in Multiple Myeloma

August 10th 2020

Looking at GRIFFIN Trial Data

August 10th 2020

A Look at the ENDURANCE Trial

August 10th 2020

Newly Diagnosed Multiple Myeloma

August 10th 2020

Introduction to Multiple Myeloma

August 10th 2020

Interim REFLECT Analysis Reconfirms Efficacy, Safety of Rituximab Biosimilar in DLBCL

August 7th 2020

Manfred Welslau, MD, discusses findings from the REFLECT interim analysis that reconfirmed the activity of the rituximab biosimilar SDZ-RTX, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with diffuse large B-cell lymphoma.

Dr. Raje on Efficacy With Melflufen in Triple-Refractory Myeloma

August 6th 2020

Noopur S. Raje, MD, discusses recent findings with melflufen in relapsed/refractory multiple myeloma.

CD30-Targeted CAR T-Cell Therapy Elicits Durable Responses in Relapsed/Refractory Hodgkin Lymphoma

August 6th 2020

A CD30-targeted CAR T-cell therapy was found to elicit a high rate of durable complete responses (CRs) in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma.

Dr. Shaughnessy on Addressing Challenges With CAR T-Cell Therapy in Hematologic Malignancies

August 5th 2020

Paul J. Shaughnessy, MD, discusses the challenges faced with CAR T-cell therapy in hematologic malignancies.

Dr. Balzarotti on Questions With Consolidation and Maintenance Therapy in R/R DLBCL

August 5th 2020

Monica Balzarotti, MD, discusses remaining questions regarding consolidation and maintenance therapy in relapsed/refractory diffuse large B-cell lymphoma.

Shaughnessy Speaks to the Rapidly Evolving Role of CAR T-cell Therapy in Hematologic Malignancies

August 5th 2020

Paul J. Shaughnessy, MD, discusses how CAR T-cell therapy is being utilized in hematologic malignancies, challenges faced with this modality, and ongoing research efforts being made to better leverage its use.

Dr. Palmer on the Treatment Landscape of aGVHD

August 4th 2020

Jeanne M. Palmer, MD, discusses the current treatment landscape of acute graft-versus-host disease.

FDA Grants Aspacytarabine Fast Track Status for Older Patients With AML

August 4th 2020

The FDA has granted a fast track designation for aspacytarabine as treatment for acute myeloid leukemia in adults aged 75 years or older who have comorbidities that preclude the utilization of intensive induction chemotherapy.

Non-Steroid Treatments Lead Progress in GVHD Management

August 4th 2020

Jeanne M. Palmer, MD, discusses advances made with non-steroid treatments in graft-versus-host disease and how biomarkers such as ST2 and REG-3 alpha might help to inform future treatment decisions.

Tisagenlecleucel Shows Clinically Meaningful Benefit in Relapsed/Refractory Follicular Lymphoma

August 4th 2020

Tisagenlecleucel was found to elicit clinically meaningful activity in patients with relapsed/refractory follicular lymphoma, meeting the phase 2 ELARA trial’s primary end point of complete response rate.

Dr. Palmer on Complications of Acute Graft-Versus-Host Disease

August 3rd 2020

Jeanne M. Palmer, MD, discusses common complications associated with acute graft-versus-host disease.

FDA Approves Tafasitamab Plus Lenalidomide in Relapsed/Refractory DLBCL

August 1st 2020

The FDA has approved tafasitamab-cxix (Monjuvi) in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant.